Immuno-Oncology | Specialty

Durvalumab FDA Approval for Bladder Cancer

April 22nd 2017

Bladder Cancer: Paradigm Changing Advances in Treatment

April 22nd 2017

Revolutionary Advances for Treating Urothelial Carcinoma

April 22nd 2017

Dr. Pinato on Study of Immune-Tolerogenic Pathways in Primary and Metastatic HCC

April 21st 2017

David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma.

Dr. Slovin on the Future of Immunotherapy in Prostate Cancer

April 21st 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

Dr. Nambiar on Next Steps with Galectin-1 for Head and Neck Cancer

April 21st 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses the next steps with targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in patients with head and neck cancer.

Dr. Abi-Jaoudeh Discusses Potential of Immunotherapy in Advanced HCC

April 20th 2017

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.

Future Directions for Metastatic Breast Cancer

April 19th 2017

Unmet Needs for Metastatic Breast Cancer

April 19th 2017

Patient Selection for Eribulin in Breast Cancer

April 19th 2017

Preclinical Observations on Eribulin for Breast Cancer

April 19th 2017

Dual MOA for Eribulin in Breast Cancer

April 19th 2017

Role of MOA When Choosing Breast Cancer Chemotherapy

April 19th 2017

Evolution of Chemotherapy for Metastatic Breast Cancer

April 19th 2017

Optimizing Chemotherapy for Metastatic Breast Cancer

April 19th 2017

Chemotherapy Use for Breast Cancer Subtypes

April 19th 2017

Chemotherapy for Metastatic Breast Cancer in 2017

April 19th 2017

Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC

April 19th 2017

Daniel B. Costa, MD, PhD, MMSc, associate professor of medicine at Harvard Medical School, medical staff, Hematology/Oncology, medical director of the Cancer Clinical Trials Office, and Medical Center Thoracic Oncology Group Leader, of Beth Israel Deaconess Medical Center, discusses biomarkers beyond PD-L1 in development for immunotherapy in patients with non–small cell lung cancer (NSCLC).

Tripathy Offers Insights on Future of Breast Cancer From SABCS, ASCO

April 19th 2017

The 34th Annual Miami Breast Cancer Conference® featured a recap of significant research from the 2016 ASCO Annual Meeting and the 2016 San Antonio Breast Cancer Symposium.

Dr. Monk on Immunotherapy for Gynecologic Cancer

April 19th 2017

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.